Enteric Disease Testing Market Size, Trend & Opportunity Analysis Report, By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End User (Hospital Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes), Global & Regional Forecast 2026-2035
Global Enteric Disease Testing Market Size, Opportunity Analysis and Forecast, 2026-2035
Enteric Disease Testing Market Overview and Definition
The Global Enteric Disease Testing Market was valued at USD 4.08 billion in 2025, and is projected to reach USD 5.76 billion by 2035, growing at a CAGR of 3.5% during the forecast period 2026 to 2035. North America commands the largest revenue share, driven by robust healthcare infrastructure and the concentration of key diagnostic players. Asia-Pacific is the fastest-growing region, propelled by high disease prevalence, expanding healthcare access, and rising public and private investment in diagnostics. By product type, reagents and consumables generate the largest share, whilst equipment is the fastest-growing segment. Bacterial enteric disease accounts for the dominant share by disease type, and hospital laboratories lead in end-user revenue.
Key Market Trends & Analysis
- Global Enteric Disease Testing Market reached USD 4.08 billion in 2025, reflecting expanding gastrointestinal diagnostics industry analysis worldwide.
- Enteric Disease Testing Market is projected to grow at a CAGR of 3.5% during forecast period 2026-2035.
- Market size is forecasted to reach USD 5.76 billion by 2035, driven by rising enteric infection prevalence globally.
- Rising diarrhoeal disease burden affecting 550 million individuals annually significantly accelerates enteric disease diagnostic testing demand growth.
- North America dominates regional market share through advanced healthcare infrastructure, strong reimbursement frameworks, and concentrated diagnostic industry players.
- Reagents and consumables segment leads product revenue share due to recurring procurement cycles across hospital and reference laboratories.
- Molecular diagnostics segment records fastest growth trends, supported by multiplex PCR adoption, rapid results, and superior diagnostic sensitivity.
- Hospital laboratories maintain dominant end-user revenue share, benefiting from increasing inpatient testing volumes and rapid molecular diagnostics integration.
- United States contributes 90.35% of North American regional revenue, supported by structured reimbursement policies and advanced diagnostic infrastructure.
- In February 2025, bioMérieux received FDA clearance for BIOFIRE FILMARRAY GI Panel Mid multiplex PCR diagnostic platform.
Enteric Disease Testing Market Size and Growth Projection
- Market Size in 2025: USD 4.08 Billion
- Market Size by 2035: USD 5.76 Billion
- CAGR: 3.5% from 2026 to 2035
- Base Year: 2025
- Forecast Period: 2026-2035
- Historical Data: 2022-2024
Enteric disease testing market comprises all the diagnostic tools, technology and services involved in the detection of diseases caused by bacterial, viral, and parasitic pathogens within the gut. The market comprises reagents, consumables, instruments used for both molecular diagnostics and immunodiagnostics processes, along with the clinical and laboratory setup where the tests are conducted. Some of the pathogens tested include but are not limited to C. Difficile, Campylobacter, E. coli, H. pylori, Salmonella, Shigella, Vibrio cholerae, norovirus, rotavirus, Cryptosporidium, and Giardia. Specimens analyzed include feces, blood, and other body fluids. The target end users include hospitals, pharmaceuticals, and biotechnology firms, with tests ranging from simple culture methods to advanced multiplex panels and point-of-care immunoassays.
However, the importance of this particular market has become even more apparent due to continued burden of food-borne and water-borne infections on global health. According to statistics provided by WHO, about 550 million people get affected by such conditions each year, among which as many as 220 million people are infants younger than five years old, hence the necessity of timely detection of pathogens. Introduction of multiplex molecular diagnostics methods decreases the time required for result detection to less than an hour. Government initiatives in various countries have set regulatory framework that includes FDA approval in the USA and IVDR compliance in Europe. Rising disposable income in developing nations together with increased awareness about diagnostics and healthcare infrastructure development has translated unmet demand for testing into commercial opportunity.
For instance, In February 2025, bioMérieux received U.S. FDA clearance for its BIOFIRE FILMARRAY Gastrointestinal Panel Mid, a multiplex PCR test detecting 11 bacterial, viral, and parasitic pathogens from a single stool sample in approximately one hour, marking a significant advancement in accessible, rapid enteric diagnostics.
Recent Developments in the Enteric Disease Testing Industry
- In February 2025, bioMérieux received FDA approval for its new BIOFIRE FILMARRAY GI Panel Mid, which is a midplex molecular diagnostic tool that can simultaneously detect 11 pathogens associated with causing gastroenteritis from a single sample of feces. The panel takes roughly two minutes of hands-on setup time and provides results within an hour using bioMérieux's FILMARRAY 2.0 and Torch PCR instruments. The product was launched in the United States during the second half of 2025.
- In February 2025, The CE mark was obtained by Biomerica Inc. from the IVDR 2017/746 Regulation of the European Union, regarding In Vitro Diagnostic Medical Devices for their food intolerance testing kits specifically designed for patients suffering from Crohn's Disease and Ulcerative Colitis. This certificate validates that they meet the high standards set by the European Union in terms of safety and performance.
- In January 2024, Trinity Biotech has announced its acquisition of CGM related assets from Waveform Technologies Inc. This indicates the plan of Trinity Biotech to expand into other diagnostic segments besides those of infectious diseases while keeping intact their core strengths in reference laboratories and point of care tests. It also shows that the existing strengths of Trinity Biotech in diagnosing infectious diseases and measuring hemoglobin, among others, go hand-in-hand with the trend within the diagnostics industry towards creating multiple condition platforms for increased business sustainability.
- In January 2023, This was done through the creation of a partnership between Trinity Biotech and imaware Inc., with the two joining hands to leverage their strengths. Specifically, Trinity Biotech brought in its expertise in reference laboratory, while imaware provided an innovative digital health platform for delivering decentralized healthcare diagnostics, such as infectious disease and GI panel testing.
Enteric Disease Testing Market Dynamics: Drivers, Restraints, Opportunities, Trends and Challenges
Rising global burden of enteric infections is driving sustained demand for diagnostic testing across all market segments.
The group of enteric infections presents one of the biggest health concerns caused by infectious diseases. According to the information provided by the WHO, diarrhea is listed as the third main factor causing child deaths up to 59 months old, and there are about 1.7 billion cases annually. For instance, in India, the mortality rate resulting from the disease in any age category in 2019 was estimated as 632,344 people, with a prevalence rate of 45 per 100,000. The wide distribution of C. difficile, Salmonella, E. coli, H. pylori, Campylobacter, and cholera in both developed and developing countries creates a demand for the products related to enteric diseases test kits.
High cost of advanced diagnostic platforms and regulatory complexity are limiting market penetration in resource-constrained settings.
Though there is a definite medical case for more tests, the high cost of sophisticated molecular diagnostic systems and kits poses a substantial barrier to use in lower and middle-income nations, which are typically where enteric infection rates are the highest. The financial outlay required for PCR-based technology, alongside the need for trained staff and robust cold chain facilities, limits adoption outside the larger urban hospitals. Moreover, regulatory pressures have been steadily rising as well; with the EU's new approach to the CE mark under the IVDR making it much harder to get products into the market.
Expanding diagnostics access in Asia-Pacific and Africa presents commercially significant growth opportunities for enteric testing providers.
The potential that is not yet utilized in developing nations is considerable. There are countries like those in the Asia-Pacific region, especially China and India, which are able to combine large populations with improvements in their healthcare system, higher per capita income levels, and increased government spending in laboratories. The amount spent by the Indian government on healthcare has been on the rise, and its initiatives toward universal health care have resulted in an expansion of diagnostic testing facilities. In the case of Africa, where there is a high prevalence of enteric diseases, international assistance is being used to improve POC test facilities.
Antimicrobial resistance patterns and evolving pathogen profiles present clinical and commercial challenges for assay developers.
AMR is transforming how enteric diseases are managed clinically to a level where diagnostics have become more important. The need for detection of pathogens together with their resistance profile is becoming increasingly important in determining appropriate treatment; something that simple immunoassays lack the capability to do, creating pressure for resistance biomarkers to be included in multiplex molecular assays, thus increasing their development challenges and costs. Also, there are regional changes in the types of pathogens seen because of factors such as climate change, migration, and food globalisation, thus requiring constant updating of the assays and validations of manufacturers' products.
Multiplex molecular diagnostics, point-of-care platforms, and digital health integration are transforming the enteric testing landscape.
The trend that has been having the greatest impact on the market in a commercial sense is the use of multiplex PCR panels that screen for various bacterial, viral, and parasitic pathogens using one sample in less than an hour. The effect of this trend is the loss of the competitive edge that is associated with the process of sending samples to be screened by a reference laboratory because hospitals can now perform testing themselves. With point-of-care technology, testing services are reaching outpatients and people in rural settings as well as being performed in homes via telemedicine partnerships like those between Trinity Biotech and imaware.
Where Are the Biggest Opportunities in the Enteric Disease Testing Market?
- Multiplex PCR Panel Development: Simultaneous detection of multiple GI pathogens from one sample reduces time-to-treatment and improves clinical outcomes.
- Point-of-Care Testing Expansion: Rapid, portable assays are unlocking diagnostic access in outpatient, rural, and home-based care settings globally.
- Developing Market Penetration: High enteric disease burden in Asia, Africa, and Latin America represents large untapped commercial opportunity for cost-effective tests.
- Antibiotic Resistance Profiling: Integrating AMR markers into enteric panels addresses an urgent clinical need and differentiates premium diagnostic products.
- Paediatric Diagnostic Specialisation: Children under five carry disproportionate enteric disease burden, creating demand for age-specific, lower-volume assay formats.
- Digital Health Platform Integration: Remote specimen collection linked to reference laboratory analysis is creating new decentralised testing revenue channels.
- IVDR-Compliant European Expansion: Achieving IVDR certification under the EU's revised IVD regulation opens access to a well-funded, regulated market for GI diagnostic products.
Enteric Disease Testing Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 4.08 Billion |
Market Size by 2035 | USD 5.76 Billion |
CAGR (2026-2035) | 3.5% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Product Type: Reagents and Consumables, Equipment By Technique: Molecular Diagnostics, Immunodiagnostics By Disease Type: Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease By End User: Hospital Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes |
Regional Analysis/Coverage | North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa) |
Company Profiles | Biomerica, Inc. | Trinity Biotech | Quest Diagnostics Inc. | bioMérieux SA | Becton Dickinson & Company | Bio-Rad Laboratories, Inc. | Coris BioConcept | Meridian Bioscience Inc. | Abbott Laboratories | DiaSorin S.p.A. |
Dominating Segments in the Enteric Disease Testing Market
Reagents and consumables dominate product revenue, underpinned by recurring procurement cycles across global laboratory networks.
Revenue contributions from reagents and consumables were the highest in the year 2022 and would continue to maintain their position at the top throughout the forecast period due to the necessity to use new reagents for each test conducted irrespective of the previous equipment purchased. The steady demand makes it an attractive market with regular revenue streams compared to equipment revenues. The market also gains from increased adoption of various diagnostic platforms in different laboratory settings, with each becoming a captive market for reagent providers. A broad range of reagents available from various suppliers contributes to increased usage in laboratories in both advanced and emerging countries. Cost-effective local reagents can be used along with branded products offered by the major diagnostics firms.
For instance, In February 2025, Biomerica received EU IVDR CE marking for its food intolerance diagnostic products targeting Crohn's Disease and Ulcerative Colitis patients, validating the company's reagent and consumable portfolio against Europe's most stringent in vitro diagnostic regulatory standards and opening a new commercial channel in the EU market.
Bacterial enteric disease dominates disease type, driven by the highest global pathogen prevalence and broadest assay availability.
The enteric bacteria segment was the dominant player among all segments in terms of market share, and it was expected to maintain its position by registering the fastest CAGR during the forecast period due to both high prevalence and increasing demand for diagnosis. Enteric bacteria such as C. difficile, Salmonella, Campylobacter, E. coli, Shigella, H. pylori, and Vibrio cholerae cause a large percentage of the global cases of infectious diarrhoea leading to morbidity and mortality. The increase in awareness of the significance of proper bacterial pathogen identification in relation to antibiotic stewardship programs is further driving the adoption of tests. There is an abundance of commercial tests available, ranging from immunoassays such as immunochromatographic strips to multiplex PCR-based assays, for the detection of bacterial pathogens.
For instance, In February 2025, bioMérieux received FDA clearance for the BIOFIRE FILMARRAY GI Panel Mid, which detects seven bacterial pathogens including Campylobacter, C. difficile, Salmonella, Shigella, and STEC, reinforcing molecular diagnostics as the technology of choice for comprehensive bacterial enteric disease identification in hospital settings.
Hospital laboratories lead end-user revenue and are the primary engine of volume growth for enteric disease testing globally.
In 2022, hospital labs emerged as the largest end-user category in terms of revenue contribution, with a steady projection of recording the highest CAGR throughout the forecasted period due to their critical involvement in clinical pathways pertaining to gastrointestinal infections that are acute in nature. Growing admissions in hospitals, along with increased access to health insurance and incorporation of rapid molecular tests within the standard procedures followed during emergencies and inpatients' care, has been driving volume generation in this category of end-user. Preference of clinicians to conduct tests from hospital labs because the test results would impact their decision on treatment makes this category inherently better than other categories, such as reference labs and research.
For instance, In January 2025, Thermo Fisher Scientific launched a new multiplex PCR panel designed for the simultaneous detection of 20 gastrointestinal pathogens, specifically targeting hospital laboratory workflows and significantly reducing the time required for comprehensive enteric pathogen identification in acute care settings.
Molecular diagnostics is the fastest-growing technique, driven by multiplex capability, speed, and superior sensitivity over immunoassays.
Although immunodiagnostics accounted for a greater share of revenue, it was molecular diagnostics that experienced a higher CAGR due to PCR and nucleic acid amplification methods becoming the standard in hospital labs worldwide. From a clinical point of view, this method offers multiple benefits, including enhanced sensitivity and specificity, a wider range of pathogens that can be detected through one sample, and rapid results that affect patient treatment decision-making on the day of diagnosis. Molecular methods have found increasing applications within research settings where universities and pharmaceuticals use multiplexing tests to study the spread of pathogens and conduct antibiotic susceptibility tests. In addition, equipment suitable for molecular testing has become widely available for use in non-academic laboratories.
For instance, In February 2025, bioMérieux's BIOFIRE GI Panel Mid, cleared by the FDA as a PCR-based midplex molecular diagnostic, exemplifies the segment's direction: one hour to result, 11 pathogens detected, two minutes of hands-on preparation, redefining the speed and accessibility benchmark for molecular enteric testing.
Regional Insights in the Enteric Disease Testing Market
North America leads the global enteric disease testing market, driven by advanced infrastructure, strong reimbursement, and a dense player ecosystem.
The North American region had the largest revenue share of the global market of enteric disease testing in 2022 and would continue to dominate the forecast period. This is mainly because of the dominance of major diagnostics players like Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Meridian Bioscience, Quest Diagnostics, and Biomerica in the region. In addition, the United States enjoys an established system of reimbursements for hospitals laboratories to invest in state-of-the-art enteric disease diagnosis systems due to their involvement in Medicare and Medicaid programs. The involvement of governmental agencies such as the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) in enteric disease surveillance and regulations is instrumental for the promotion of diagnostic demand on a structured basis.
In February 2025, bioMérieux obtained U.S. FDA clearance for the BIOFIRE FILMARRAY GI Panel Mid, a multiplex PCR test detecting 11 GI pathogens in one hour, commercially launched in the U.S. by mid-2025 and directly strengthening the North American molecular diagnostics leadership position.
Europe's enteric disease testing market is expanding, shaped by IVDR regulation, cross-border travel-linked disease, and digital diagnostics investment.
The enteric disease testing market value in Europe was estimated to be USD 606 million in 2024, with its growth supported by the burden of gastrointestinal diseases, advanced health monitoring systems, and an effective health policy response system. The EU IVDR regulation (2017/746) for all in vitro diagnostic medical devices has set very high standards for these tests in Europe; this will make the entry difficult for smaller companies in the market. The advanced laboratory networks of hospitals in countries such as Germany, France, and the United Kingdom are fast adopting multiplex diagnostic testing technologies. Traveling to Europe from endemic countries will create diagnostic needs for enteric pathogens. In particular, imported cases of Salmonella, Campylobacter, and E. coli are monitored regularly.
For instance, In February 2025, Biomerica received EU IVDR CE marking for its gastrointestinal food intolerance diagnostic products targeting Crohn's Disease and Ulcerative Colitis, with the certification positioning the company for product launch across the European market under the continent's tightened IVD regulatory framework.
Asia-Pacific is the fastest-growing enteric disease testing market, powered by massive disease burden, rising incomes, and expanding diagnostic infrastructure.
The Asia-Pacific region is projected to witness the highest CAGR in the regional enteric diagnostics market. The reason behind this lies in the combination of several factors, which makes the Asia-Pacific region the commercially most active area in terms of enteric diagnostics globally. First of all, it should be noted that China and India constitute about 30 percent of the global population, and both countries have a high incidence rate for E. coli, Salmonella, cholera, and H. pylori. Moreover, both countries have seen fast development of the infrastructure of their healthcare laboratories and increased disposable income. China's healthcare reforms and India's drive towards health care coverage for all people lead to the fact that enteric diagnostics becomes the target of investments in both countries.
For instance, In November 2024, India's Namo Bharat Rapid Rail trial and continued USD 30.2 billion healthcare infrastructure investment signalled the country's accelerating commitment to health system capacity, indirectly expanding the hospital laboratory base through which enteric disease testing volumes are primarily generated.
LAMEA represents the emerging frontier for enteric disease testing, with unmet diagnostic needs and infrastructure investment creating structured long-term opportunity.
While the LAMEA area is made up of some of the highest-prevalence regions for enteric diseases, there is a corresponding shortage of diagnostic testing capability, which makes for an excellent market opportunity for those who are ready to adjust their products and pricing to the regional conditions. In Latin America, Brazil and Argentina serve as anchor markets for diagnostic capability infrastructure, with continuous investments into hospital modernization and development driven not only by government budgetary spending but by healthcare sector expansion as well. In contrast, the Middle East offers different dynamics; countries like the UAE and Saudi Arabia feature high-spending healthcare sectors and investment into premium diagnostics equipment, coupled with pilgrim-linked exposure to enteric diseases through travel during the Hajj season.
For instance, In May 2023, Etihad Rail signed a 20-year strategic logistics partnership with DHL Global Forwarding, accelerating the UAE's supply chain infrastructure, which in turn supports the distribution and cold chain logistics essential for time-sensitive diagnostic reagents and consumables reaching LAMEA-region laboratories.
How Can Stakeholders Benefit from the Enteric Disease Testing Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
